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Summary. Background: Inherited thrombophilia is only
weakly associatedwith recurrence in patients with a first venous
thrombosis (VT). In spite of this, thrombophilia testing is often
performed in these patients. Positive results may influence
patientmanagement suchasprolongedanticoagulant treatment
or intensified prophylaxis in high-risk situations. Objective: To
investigate whether thrombophilia testing reduces the risk of
recurrent VT by virtue of these management alterations.
Methods: From a large case–control study of patients (MEGA
study), aged 18–70 years, with a first VT between 1999 and
2004, we selected 197 patients who had had a recurrence during
follow-up.We compared the incidence of thrombophilia testing
to that of a control cohort of 324 patients. We calculated the
odds ratio (OR) for recurrent thrombosis in tested vs. non-
tested patients. Only patients whowere tested before recurrence
were regarded as tested. All first and recurrent thrombotic
eventswere objectively confirmed.Results:Thrombophilia tests
were performed in 35% of cases and in 30% of controls. The
OR for recurrence was 1.2 [95% confidence interval (CI) 0.9–
1.8] for tested vs. non-tested patients. After correction for age,
sex, family history, geographic region, presence of clinical risk
factors, and year of first VT, the OR remained unchanged.
Discussion: Thrombophilia testing in patients with a first VT
does not reduce the incidence of recurrence in clinical practice.
Keywords: case–control study, factor V Leiden, inherited
thrombophilia, prothrombin 20210A mutation, recurrence,
testing, venous thromboembolism.
Introduction
Clinical risk factors for venous thrombosis (VT), such as recent
surgery, immobilization, malignancy or pregnancy, are present
in only half of all cases [1]. The discovery of various inherited
thrombophilias, such as deficiencies of antithrombin, protein S
and protein C, and the factor V Leiden and prothrombin
20210A mutations, has led to increased insights into the
multicausal etiology of VT. These inherited thrombophilias are
found in approximately 50% of patients with VT [2], and
testing for thrombophilia is often performed [3]. Its use,
however, is widely debated [4–7].
The presence of inherited thrombophilia is, at best, a weak
predictor of recurrence in patients with a first episode of VT [8–
11]. There are currently no clinical trials that compare different
management strategies for patients with thrombophilia who
have had a first VT. Management recommendations for
patients with inherited thrombophilia, such as those in the
seventh ACCP Guideline for Antithrombotic Therapy for
Venous Thromboembolic Disease, are therefore graded level 2,
meaning that individual patients or physicians valuesmay lead
to different choices [12]. This may lead to different hospital or
regional guidelines onwho to test for thrombophilia and on the
treatment of patients who have had these tests.
Potential consequences of identifying a thrombophilic defect
in a patient with a first VT include prolonging the initial
anticoagulation period beyond 3–6 months, and adopting a
more vigorous prophylactic regimen in high-risk situations
such as surgery, immobilization, pregnancy, or the postpartum
period. These strategies may reduce recurrence, but need to be
balanced against hemorrhagic complications of anticoagulant
treatment. In this study, we hypothesized that thrombophilia
testing reduces the risk of recurrent thrombosis as a conse-
quence of such management alterations.
Materials and methods
The Multiple Environmental and Genetic Assessment of risk
factors for venous thrombosis (MEGA) study is a large
population-based case–control study that includes 5051
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patients, aged 18–70 years, with a first episode of VT between
1999 and 2004 [13]. In the current case–cohort study, we
selected participants who were referred to either one of three
anticoagulation clinics for a second episode of treatment for
VT during the follow-up period until July 2007 (potential
cases). We randomly sampled 385 patients who were enrolled
into the MEGA study. These patients were frequency
matched on the potential cases for age, sex, year of
thrombotic event, and geographic region (potential controls).
Only patients with proximal deep vein thrombosis and/or
pulmonary embolism were included in the present analysis, as
other venous thrombotic manifestations (such as upper
extremity VT or superficial VT) may not carry the same
risk of recurrence.
Confirmation of recurrent episodes was retrieved from the
patients treating physician and hospital records. We excluded
potential cases in whom recurrence was not confirmed by
objective tests. All charts were reviewed for the presence of tests
for activated protein C (APC) resistance, the FV Leiden
mutation or prothrombin 20210A mutation, and antithrom-
bin, protein C and protein S levels. If any of these tests were
performed within a year after the first event, we regarded
patients as tested. The presence of risk factors during the first
VTwas assessed with structured questionnaires. Family history
was regarded positive when one or more first-degree relatives
had ever experienced VT.
For research purposes, DNA samples were obtained from
each participant either by blood draw or buccal swab 3 months
after cessation of anticoagulation or during anticoagulant
therapy, in patients who continued therapy for over 1 year. A
detailed description of blood collection and DNA analysis for
the FV Leiden mutation and the prothrombin 20210A
mutation in the MEGA study has been published previously
[13]. The results were not disclosed to the participants or their
treating physicians.
Multivariate logistic regression was used to calculate the
odds ratio (OR) for recurrent VT in tested vs. non-tested
patients. We adjusted for age (continuous variable), sex, year
of thrombotic event, geographic region, family history, and
presence of a clinical risk factor that provoked the first VT
[surgery, immobilization or trauma, pregnancy, postpartum
period until 6 weeks, and use of an oral contraceptive pill
(OCP) or hormone replacement therapy (HRT)]. A sample
size of 200 patients per group would suffice to detect an OR
of 0.5 with a type I error of 0.05 (significance level) and a
type II error of 0.20 (power 80%), assuming that approxi-
mately 30% of patients with a first episode of VT are tested
for inherited thrombophilia. Additionally, the effect of
thrombophilia testing was analyzed after stratification for
the presence or absence of the FV Leiden mutation or the
prothrombin mutation as determined in the testing for
research purposes.
All participants provided written informed consent, and this
study was approved by the institutions Medical Ethics
Committee. All analyses were performed using SPSS statistical
software (version 12.0.2, SPSS Inc., Chicago, IL, USA).
Results
In total, 277 participants from the original MEGA study were
referred to one of the three selected anticoagulation clinics for a
second episode of VT. The medical records of 258 of these 277
potential cases (93%) and of 361 of 385 potential controls
(94%) were available for review. Twenty-seven cases and 37
controls were excluded because of a known malignancy. An
additional 34 of the potential cases were excluded because the
diagnosis of recurrent thrombosis could not be objectively
confirmed. Thus, 197 cases and 324 controls were included in
this analysis. DNA samples were available for 487 of 521
patients (93%); the overall incidence of the FV Leiden
mutation was 14%, and that of the prothrombin 20210A
mutation was 6%. Characteristics of these patients are given in
Table 1.
Treating physicians tested for thrombophilia after the first
episode of VT in 68 (35%) cases and in 97 (30%) controls.
Three cases, for whom it could not be determined whether or
not they were tested, were regarded as not tested. The OR for
recurrence in tested vs. non-tested patients was 1.2 [95%
confidence interval (CI) 0.9–1.8; Table 2]. Adjustment for age,
sex and the presence of a clinical risk factor before the first
thrombotic episode did not affect the OR (1.2, 95% CI 0.8–
1.9). In patients with either the FV Leiden mutation or the
prothrombin mutation, the OR for recurrence was 0.8
(95% CI 0.3–2.6), and it was 1.3 (0.8–2.1) in patients without
these mutations (Table 2).
Table 1 Patient characteristics
Patients
with
recurrence
(cases)
Patients
without
recurrence
(controls)
No. of patients 197 324
Male sex, n (%) 120 (61) 179 (55)
Mean age, years (SD) 50 (13) 49 (13)
Treatment duration of first VTE (%*)
1–3 months 27 28
4–6 months 62 66
7–12 months 6 4
> 12 months 5 3
Risk factors for first VTE, n (%)
Surgery/trauma/immobilization 48 (24) 100 (31)
Pregnancy 3 (2) 15 (5)
OCP/HRT 40 (20) 79 (24)
Idiopathic 106 (54) 130 (40)
Positive family history for VTE 62 (32) 79 (24)
Factor V Leiden mutation, n (%) 30 (16)§ 36 (12)–
Prothrombin 20210A mutation, n (%) 11 (6) 17 (6)
VTE, venous thromboembolism; OCP, oral contraceptive pill; HRT,
hormone replacement therapy. *Percentage of the number of patients
for whom the initial treatment duration was retrievable. Family his-
tory was regarded as positive when one or more first-degree family
members had ever experienced VTE. Percentage of the number of
patients for whom DNA samples were available. §Including one
homozygous carrier and one compound heterozygous carrier.
–Including four compound heterozygous carriers.
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Women were more often tested than men (35% vs. 26%), as
were patients with a positive family history for VT (39% vs.
26%), younger patients (39% vs. 18% for first vs. fourth
quartile of age), and patients with idiopathic or hormone-
related VT (32% for OCP/HRT-provoked VT, 33% for
idiopathic VT, and 21% for VT provoked by surgery, trauma
or immobilization; Table 2). ORs for recurrent thrombosis in
tested vs. non-tested individuals in these subgroups are given in
Table 2.
Discussion
We hypothesized that patients with a first VT who are tested
for inherited thrombophilia have a reduced risk of recurrence
by virtue of management alterations, such as prolongation of
initial anticoagulant treatment or intensified prophylaxis dur-
ing high-risk situations. In this study, however, we found that
tested patients do not have a different recurrence risk from
non-tested patients. These results were similar in the subgroup
of patients with the FV Leiden mutation or the prothrombin
mutation, as determined by research testing. A possible
explanation for the absence of an effect of testing may be that
in clinical practice, thrombophilia tests are regularly per-
formed, but the results are often not used for management
decisions in that particular patient. This was confirmed in a
recent survey among Dutch physicians who ordered tests for
inherited thrombophilia [3].
Strikingly, we found that in the subgroup of women with an
OCP-provoked or HRT-provoked VT, testing for thrombo-
philia was associated with an increased risk of recurrence. We
hypothesized that an explanation, besides chance variation,
could be that women who have had an OCP/HRT-provoked
VT do not discontinue the use of the OCP or HRT after they
are found to have no thrombophilia. However, the percentages
of women who continued oral contraceptive use after their VT
was the same for tested and non-tested women (18% and 17%,
respectively), and for women who were tested and found not to
have the FV Leiden mutation or the prothrombin mutation
(18%). Therefore, we were not able to explain the cause of the
increased recurrence risk in tested women with an OCP/HRT-
provoked VT.
In spite of our efforts to collect data for each individual
patient of this large cohort, some information was not
retrievable. First, we were only able to analyze the influence of
the most common inherited thrombophilias, and second, we
did not assess in how many patients the test results led to
management alterations. However, as the incidence of
deficiencies of the natural anticoagulants is very low [14], we
are confident that knowledge of other thrombophilia test
results would not affect our conclusions. The second limita-
tion is also a major strength, as the difference in observed
recurrent VT between tested and non-tested patients reflects
the current clinical practice of thrombophilia testing. Finally,
we cannot rule out the presence of unknown patient-specific
factors, associated with an increased risk of recurrent events,
that lead physicians to order tests in these patients. This is not
a likely explanation for the absence of a positive effect of
testing, as we cannot think of any other factors, others than
those that we have corrected for, that may influence the
individual physicians decision to test for thrombophilia and
are clearly associated with an increased risk of recurrence.
Strengths include the few patients lost to follow-up (7%) and
the objective confirmation of first and recurrent VT events, as
well as thrombophilia tests, through source data verification.
Furthermore, the patients originated from three different
geographic regions in The Netherlands, and as we found no
regional differences, it is likely that these results apply to the
entire country.
We conclude that thrombophilia testing in patients with a
first VT, as it is currently used in clinical practice, does not
reduce the incidence of recurrence. Ideally, the value of testing
should be investigated in a trial in which the tests have clear and
uniform consequences. This was the purpose of a randomized
trial (Dutch trial register, trial no. NTR784; http://www.
trialregister.nl) that has recently been stopped due to slow
recruitment. Nevertheless, such a trial could only test one or a
few of a myriad of potential consequences of a positive test, so
the judgement of the value of testing for thrombophilia will
ideally be based on experimental and observational data. With
the current knowledge, the value of routine testing of patients
with a first VT remains questionable, and may lead to
overtreatment with hemorrhagic complications or unnecessary
concern in those tested positive [15,16].
Table 2 Incidence of thrombophilia tests in cases and controls, and odds
ratios for recurrent venous thrombosis in tested vs. non-tested patients
Subgroups
% tested Odds ratios
for recurrence
(tested vs.
non-tested)*Cases Controls
All 35 30 1.2 (0.8–1.8)
Quartiles of age (in years)
18.3–40.1 (n = 130) 51 39 1.9 (0.8–4.6)
40.1–50.9 (n = 130) 39 35 1.1 (0.4–2.5)
51.1–60.9 (n = 131) 26 29 0.9 (0.4–2.2)
61.0–69.8 (n = 130) 24 18 1.0 (0.4–2.9)
Sex
Men 31 26 1.1 (0.6–2.0)
Women 41 35 1.4 (0.7–2.9)
Risk factors for first venous thrombosis
Surgery/trauma/immobilization 23 21 1.2 (0.5–3.1)
OCP/HRT 60 32 3.4 (1.3–8.6)
Non/idiopathic 30 33 0.8 (0.5–1.6)
Family history of venous thrombosis
Present 47 39 1.5 (0.7–3.1)
Absent 29 26 1.1 (0.7–1.9)
Thrombophilia
Present 33 33 0.8 (0.3–2.6)
Absent 36 29 1.3 (0.8–2.1)
OCP, oral contraceptive pill; HRT, hormone replacement therapy.
*Adjusted for sex, age, year of first thrombotic event, presence of
clinical risk factor that provoked the first thrombotic event, and po-
sitive family history, whenever applicable. Either factor V Leiden
mutation or prothrombin 20210A mutation.
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